Terazosin Capsule
Product Images NDC 68788-4064

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 68788-4064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure 01)

Figure 1 from Study 1 shows two line graphs comparing Terazosin and placebo over three months. The left graph depicts mean change in total symptom score from baseline, showing greater reduction with Terazosin. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with Terazosin demonstrating a higher increase than placebo.*

FDA Label Image

Image Description (Figure 02)

A line graph titled "Mean Change in Total Symptom Score from Baseline" from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis shows time in months from 0 to 30, and the y-axis shows mean change from baseline ranging from 0 to -7. The graph indicates a rapid symptom score decrease within the first three months followed by a gradual decline, with data points marked by circles and some points denoted with asterisks.*

FDA Label Image

Image Description (Figure 03)

Line graph titled 'Mean Change in Peak Flow Rate from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months 0 to 30, and the y-axis shows mean change in mL/sec from baseline, ranging from 0 to 4.5. Data points indicate an increase in peak flow rate over time, with several points marked by asterisks, suggesting statistical significance at multiple intervals.*

FDA Label Image

Terazosin Hydrochloride Capsules 2mg (Image006)

Label for Terazosin Hydrochloride Capsules 2 mg, generic for Hytrin, manufactured by OrBion Pharmaceuticals Pvt. Ltd. The label includes dosing instructions in English and Spanish, storage warnings, barcode, and fields for batch and lot numbers. The capsule is described as yellow and capsule-shaped, with prescription-only status.*

FDA Label Image

Image Description (Structure001)

Chemical structure of Terazosin depicting its molecular framework including aromatic rings, nitrogen atoms, and functional groups with hydrochloride dihydrate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.